In

When you take part in TrialNet type 1 diabetes (T1D) risk screening, a few drops of blood can make a big difference. In addition to learning your risk for developing T1D—often years before symptoms appear—you’re joining the TrialNet #T1Dfamily, the world’s largest clinical trial network ever assembled to change the course of T1D.

With landmark results recently announced, the Teplizumab Prevention Study is making headlines across the country. Here, Tracy Olsten shares why her daughter Mikayla decided to join the study.

Elliot, a 17-year-old from a small village outside Bristol, recently completed treatment in the Abatacept Prevention Study. He is the first person in the United Kingdom (UK) to do so.

The Maguire family is united in fighting the war on T1D. To participate in TrialNet research, they travel from Sault Ste. Marie, Ontario, to the Hospital for Sick Children at the University of Toronto every 6 months. That's a 7.5-hour drive, often through plenty of snow!

As a nurse, Jessica Hamer was no stranger to type 1 diabetes (T1D) when her 4-year-old son Garrus started showing signs of the disease. She said, “I just kept thinking, it can’t be type 1.” But it was, and Garrus was diagnosed with the disease in the spring of 2017.

As a nurse, Jessica Hamer was no stranger to type 1 diabetes (T1D) when her 4-year-old son Garrus started showing signs of the disease. She said, “I just kept thinking, it can’t be type 1.” But it was, and Garrus was diagnosed with the disease in the spring of 2017.

Diagnosed with type 1 diabetes (T1D) at age 11, Jennifer McVean, MD, had not heard of TrialNet until she began working as a pediatric endocrinologist. Now, as part of the pediatric endocrinology team at University of Minnesota, Dr. McVean is a TrialNet advocate heavily involved in spreading the word about screening and studies.